Fig 1: (A1–A6, B1–B6, C1–C6) Immunostaining for MMP3 of the orbicularis oris in control and prinomastat groups on days 3, 7, and 14 after facial nerve injury. (D) Western blot for MMP1, MMP2, MMP3, MMP7, and MMP9 in the orbicularis oris in prinomastat and control groups. MMP1, MMP2, MMP3, MMP7, and MMP9 expression levels in control and prinomastat groups at days 0, 3, 7, and 14 after facial nerve injury. (E) Bar chart of MMP1, MMP2, MMP3, MMP7, and MMP9 at days 0, 3, 7, and 14 after facial nerve injury in the prinomastat group. (F) Bar chart of MMP1, MMP2, MMP3, MMP7, and MMP9 at days 0, 3, 7, and 14 after facial nerve injury in the control group. The error bars represent SD; scale bar: 20 μm.